Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Foamix psoriasis treatment finds favor over GSK rival
Results from the phase I/II study of betamethasone valerate 0.12% foam in plaque type psoriatic patients demonstrated that the Foamix’ product candidate was efficacious and safe. Patients also
Results from the phase I/II study of betamethasone valerate 0.12% foam in plaque type psoriatic patients demonstrated that the Foamix’ product candidate was efficacious and safe. Patients also
Approximately 100 patients will be enrolled in the US and Canada and randomized into two treatment groups, with one treatment group receiving the combination of HGS-ETR1 and bortezomib,
The submission contains data from previously reported pivotal phase III studies that met their primary efficacy endpoints of reduction in incidence in menstrual migraine. If the supplemental new
Caraco’s Meloxicam Tablets is the generic equivalent of Boehringer Ingelheim’s Mobic, a nonsteroidal anti-inflammatory drug, (NSAID) indicated for the relief of the signs and symptoms of osteoarthritis. Caraco
The companies plan to combine operations in a stock transaction valued at approximately $8.8 million. As part of the merger, a portion of existing shares of Alteon preferred
An open-label phase II safety and efficacy trial enrolled 16 post-radical prostatectomy patients. Patients enrolled in the trial had undergone this surgery at least six months prior to
The American Diabetes Association (ADA) has been a strong supporter of the bill, which it believes would accelerate medical advancements by easing existing restrictions and supporting research that
For the second quarter ended June 30, 2006, Abbott’s earnings were just over $612 million, down 30% on the previous year’s $877 million. However, the company’s diluted earnings
A six-month 1,195-patient trial named IDEAL showed that the Exelon patch (rivastigmine transdermal patch) provided benefits across a range of symptoms and that the target dose was well
In March 2006, Protiva filed a statement of claim in the Supreme Court of British Columbia against Inex Pharmaceuticals, Inex’ CEO, and three Inex directors who also served